Ascendis Pharma AS (ASND)

124.28 -1.75 (-1.39%) USD  |  NASDAQ  |  Nov 14, 16:00
124.16 -0.12 (-0.10%) After-Hours: 04:53
More

Ascendis Pharma Cash and Short Term Investments (Quarterly): 277.30M for June 30, 2024

Cash and Short Term Investments (Quarterly) Chart

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
June 30, 2024 277.30M
March 31, 2024 345.83M
December 31, 2023 441.54M
September 30, 2023 482.08M
June 30, 2023 468.50M
March 31, 2023 638.72M
December 31, 2022 788.70M
September 30, 2022 904.07M
June 30, 2022 997.74M
March 31, 2022 1.092B
December 31, 2021 772.25M
September 30, 2021 995.53M
June 30, 2021 655.27M
March 31, 2021 779.23M
December 31, 2020 884.09M
September 30, 2020 1.092B
June 30, 2020 530.35M
March 31, 2020 589.39M
December 31, 2019 669.98M
September 30, 2019 720.64M
June 30, 2019 784.93M
Date Value
March 31, 2019 782.35M
December 31, 2018 317.85M
September 30, 2018 360.61M
June 30, 2018 407.68M
March 31, 2018 429.55M
December 31, 2017 234.36M
September 30, 2017 243.03M
June 30, 2017 145.65M
March 31, 2017 168.47M
December 31, 2016 190.64M
September 30, 2016 83.61M
June 30, 2016 100.95M
March 31, 2016 115.45M
December 31, 2015 130.81M
September 30, 2015 144.30M
June 30, 2015 154.62M
March 31, 2015 166.17M
December 31, 2014 61.00M
September 30, 2014 10.04M
December 31, 2013 26.83M

Cash and Short Term Investments Definition

Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

277.30M
Minimum
Jun 2024
1.092B
Maximum
Mar 2022
705.50M
Average
669.98M
Median
Dec 2019

Cash and Short Term Investments (Quarterly) Benchmarks

Novo Nordisk AS 11.22B
Evaxion Biotech AS 4.576M
Biodexa Pharmaceuticals PLC 6.394M
NuCana PLC 14.72M
Genfit SA 85.99M